CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
Join us on June 25, 2016, for a one-day, multi-distance “Answer to Cancer” cycling event throughout New York's Lower Hudson Valley and sponsored by Bristol-Myers Squibb.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Hosted by CRI, EATI, CIMT, and AACR, register today for "Translating Science into Survival," on September 25-28, 2016, in New York City.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Cancer Immunotherapy and You" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
February 26, 2016
Jill O'Donnell-Tormey, Ph.D.
CRI and Vice President Biden’s Moonshot Initiative collaborate for the advancement of cancer immunotherapy research.
cancer immunotherapy, Coley's toxins, history, in the news
ASCO, cancer immunotherapy, cancer research, events
ASCO, cancer immunotherapy, clinical trials, events
cancer immunotherapy, in the news
anti-PD-1, cancer immunotherapy, checkpoint-inhibitor, FDA approval, melanoma
CRI’s CEO provides a preview of what to expect at the upcoming meeting of the American Society of Hematology.
cancer immunotherapy, events
cancer immunotherapy, checkpoint-inhibitor, PD-1, progress
cancer immunotherapy, clinical accelerator, clinical trials, experimental, innovation